Holen Sie sich die Stockscreener-App
2.03
0.52%
-0.01
Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten
VistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William Blair - MarketBeat
Stifel reiterates buy rating on VistaGen stock amid clinical progress By Investing.com - Investing.com Canada
Vistagen (VTGN) Advances Fasedienol for Social Anxiety Treatment - GuruFocus
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses - GuruFocus
Vistagen Therapeutics Reports Progress in Clinical Trials - TipRanks
Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline - MSN
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - sharewise
Earnings call transcript: Vistagen’s focus on innovation amid rising expenses Q1 2025 - Investing.com India
Vistagen Therapeutics Inc Reports Q1 Revenue of $0.49M, Surpassi - GuruFocus
Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Vistagen (VTGN) Reports Decrease in FY25 Revenue, Advances Key Medical Programs | VTGN Stock News - GuruFocus
Vistagen Therapeutics, Inc. SEC 10-K Report - TradingView
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For - GuruFocus
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Holdings Increased by Millennium Management LLC - Defense World
Vistagen Therapeutics Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Vistagen Earnings Preview: Late-Stage Neuroscience Biotech to Unveil FY2025 Performance - Stock Titan
Two Sigma Investments LP Has $405,000 Position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Two Sigma Advisers LP Acquires New Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Vistagen Therapeutics (NASDAQ:VTGN) Earnings Preview: What to Expect from $VTGN Amid Shifting Investor Sentiment | VTGN Stock - paginasiete.bo
VISTAGEN THERAPEUTICS Earnings Preview: Recent $VTGN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Vistagen Therapeutics (VTGN) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
VistaGen at Jefferies: Expanding Horizons in Social Anxiety Treatment By Investing.com - Investing.com Canada
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Northern Trust Corp - Defense World
Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday - Defense World
Vistagen expects phase 3 trial results by 2026 By Investing.com - Investing.com South Africa
Vistagen expects phase 3 trial results by 2026 - Investing.com India
VTGN: Vistagen Updates Timeline for Key Phase 3 Trials | VTGN St - GuruFocus
VTGN: Vistagen Updates Timeline for Key Phase 3 Trials | VTGN Stock News - GuruFocus
Vistagen On Track To Deliver Topline Data From Fasedienol Palisade-3 Phase 3 Trial - MarketScreener
Major Social Anxiety Treatment Breakthrough: Phase 3 Trial Results Coming Q4 2025What to Expect - Stock Titan
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York - sharewise
Vistagen Showcases Revolutionary Nose-to-Brain Drug Technology at Major Jefferies Healthcare Conference - Stock Titan
Breakthrough Nasal Spray Treatment Shows Promise for Depression and Social Anxiety, New Clinical Data Reveals - Stock Titan
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference - BioSpace
Ellis Martin Report: Vistagen Therapeutics Inc. (NASDAQ:VTGN) CEO Shawn SinghA Revolutionary Fast Acting Nasal Spray Targeting Social Anxiety Disorder - ABN Newswire
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Renaissance Technologies LLC - MarketBeat
254,655 Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Bought by Almitas Capital LLC - MarketBeat
Renaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Form 8-KCurrent report - ADVFN
Nantahala Capital Management LLC Boosts Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat
JPMorgan Chase & Co. Buys 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
JPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Social Anxiety Crisis: 48% of Young Adults Report Suicidal Thoughts, Treatment Gap Widens - Stock Titan
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - BioSpace
Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World
0.34%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):